Abbott Laboratories (Pakistan) Limited (PSX: ABOT) reported a remarkable 52% increase in net profit, reaching Rs7.97 billion for the year ended December 31, 2025, up from Rs5.23 billion in the previous year. The stellar performance was driven by healthy revenue growth and efficient cost management.
Read More: PAEL CY25 Profit Surges 63% to Rs3.85 Billion, Driven by Revenue Growth and Lower Finance Costs
The company’s basic earnings per share (EPS) rose sharply to Rs81.37, compared to Rs53.46 in the prior year, demonstrating strong profitability and value creation for shareholders.
Dividend Announcement
In recognition of its strong performance, Abbott Laboratories (Pakistan) Limited declared a final cash dividend of Rs40 per share (400%) for the calendar year 2025. This generous payout rewards shareholders for their confidence in the company and reflects Abbott’s robust cash generation capabilities.
Revenue and Gross Profit
Net sales climbed a healthy 10.6% year-on-year to Rs75.40 billion from Rs68.18 billion, reflecting sustained demand for the company’s pharmaceutical and consumer health products.
Cost of sales rose only marginally by 1% to Rs48.95 billion, significantly slower than revenue growth. This excellent cost control drove gross profit up 34% to Rs26.45 billion from Rs19.74 billion in the prior year, resulting in substantial gross margin expansion.
Operating Performance
On the operating front, the company experienced moderate inflationary pressures typical of the current economic environment:
| Expense Category | 2025 | 2024 | Change |
|---|---|---|---|
| Selling & Distribution | Rs11.09bn | Rs9.30bn | +19% |
| Administrative Expenses | Rs1.36bn | Rs1.17bn | +16.6% |
| Other Charges | Rs1.59bn | Rs838m | +89% |
| Other Income | Rs1.16bn | Rs723m | +60% |
Other charges spiked significantly, but this was partially offset by strong 60% growth in other income. These factors combined to boost total operating profit by 48.3% to Rs13.58 billion.
Finance Costs and Taxation
A significant increase in finance costs (up 220% to Rs75.66 million) was noted, though the absolute amount remains modest relative to operating profit. Profit before income taxes jumped 49.6% to Rs13.50 billion.
After accounting for a 46% higher income tax expense of Rs5.53 billion (reflecting the increased profitability), the company recorded a net profit of Rs7.97 billion, marking a 52% year-on-year increase.
Financial Summary
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Net Sales | Rs75.40bn | Rs68.18bn | +10.6% |
| Gross Profit | Rs26.45bn | Rs19.74bn | +34% |
| Operating Profit | Rs13.58bn | Rs9.15bn | +48.3% |
| Profit Before Tax | Rs13.50bn | Rs9.02bn | +49.6% |
| Net Profit | Rs7.97bn | Rs5.23bn | +52% |
| EPS | Rs81.37 | Rs53.46 | +52% |
| Dividend | Rs40/share | – | – |
About Abbott Laboratories (Pakistan) Limited
Abbott Laboratories (Pakistan) Limited (PSX: ABOT) is a leading pharmaceutical and healthcare company in Pakistan. Part of the global Abbott group, the company manufactures and markets a wide range of pharmaceutical products, nutritional supplements, and diagnostic solutions, serving patients and consumers across the country.
